statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell...

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H...

Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...

Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference

DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...

DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data Mural intends to nominate development...

Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Volume	87,760.00
52-Wk High	$17.00
52-Wk Low	$2.88

MURA Mural Oncology plc

About

Feed

News

Fundamentals